Close

Form 6-K Sanofi For: Jun 30

July 28, 2022 6:19 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
FALSE0001121404--12-316/30/20222022Q20.043478260869565200011214042022-01-012022-06-3000011214042022-06-30iso4217:EUR00011214042021-12-3100011214042021-01-012021-06-3000011214042021-01-012021-12-31xbrli:sharesiso4217:EURxbrli:shares0001121404ifrs-full:IssuedCapitalMember2019-12-310001121404ifrs-full:AdditionalPaidinCapitalMember2019-12-310001121404ifrs-full:TreasurySharesMember2019-12-310001121404ifrs-full:RetainedEarningsMember2019-12-310001121404ifrs-full:ReserveOfSharebasedPaymentsMember2019-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2019-12-310001121404ifrs-full:EquityAttributableToOwnersOfParentMember2019-12-310001121404ifrs-full:NoncontrollingInterestsMember2019-12-3100011214042019-12-310001121404ifrs-full:RetainedEarningsMember2020-01-012020-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001121404ifrs-full:EquityAttributableToOwnersOfParentMember2020-01-012020-12-310001121404ifrs-full:NoncontrollingInterestsMember2020-01-012020-12-3100011214042020-01-012020-12-310001121404ifrs-full:TreasurySharesMember2020-01-012020-12-310001121404ifrs-full:IssuedCapitalMember2020-01-012020-12-310001121404ifrs-full:AdditionalPaidinCapitalMember2020-01-012020-12-310001121404ifrs-full:ReserveOfSharebasedPaymentsMember2020-01-012020-12-310001121404ifrs-full:IssuedCapitalMember2020-12-310001121404ifrs-full:AdditionalPaidinCapitalMember2020-12-310001121404ifrs-full:TreasurySharesMember2020-12-310001121404ifrs-full:RetainedEarningsMember2020-12-310001121404ifrs-full:ReserveOfSharebasedPaymentsMember2020-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2020-12-310001121404ifrs-full:EquityAttributableToOwnersOfParentMember2020-12-310001121404ifrs-full:NoncontrollingInterestsMember2020-12-3100011214042020-12-310001121404ifrs-full:RetainedEarningsMember2021-01-012021-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001121404ifrs-full:EquityAttributableToOwnersOfParentMember2021-01-012021-06-300001121404ifrs-full:NoncontrollingInterestsMember2021-01-012021-06-300001121404ifrs-full:TreasurySharesMember2021-01-012021-06-300001121404ifrs-full:AdditionalPaidinCapitalMember2021-01-012021-06-300001121404ifrs-full:IssuedCapitalMember2021-01-012021-06-300001121404ifrs-full:ReserveOfSharebasedPaymentsMember2021-01-012021-06-300001121404ifrs-full:IssuedCapitalMember2021-06-300001121404ifrs-full:AdditionalPaidinCapitalMember2021-06-300001121404ifrs-full:TreasurySharesMember2021-06-300001121404ifrs-full:RetainedEarningsMember2021-06-300001121404ifrs-full:ReserveOfSharebasedPaymentsMember2021-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-06-300001121404ifrs-full:EquityAttributableToOwnersOfParentMember2021-06-300001121404ifrs-full:NoncontrollingInterestsMember2021-06-3000011214042021-06-300001121404ifrs-full:RetainedEarningsMember2021-07-012021-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-12-310001121404ifrs-full:EquityAttributableToOwnersOfParentMember2021-07-012021-12-310001121404ifrs-full:NoncontrollingInterestsMember2021-07-012021-12-3100011214042021-07-012021-12-310001121404ifrs-full:TreasurySharesMember2021-07-012021-12-310001121404ifrs-full:AdditionalPaidinCapitalMember2021-07-012021-12-310001121404ifrs-full:IssuedCapitalMember2021-07-012021-12-310001121404ifrs-full:ReserveOfSharebasedPaymentsMember2021-07-012021-12-310001121404ifrs-full:IssuedCapitalMember2021-12-310001121404ifrs-full:AdditionalPaidinCapitalMember2021-12-310001121404ifrs-full:TreasurySharesMember2021-12-310001121404ifrs-full:RetainedEarningsMember2021-12-310001121404ifrs-full:ReserveOfSharebasedPaymentsMember2021-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-12-310001121404ifrs-full:EquityAttributableToOwnersOfParentMember2021-12-310001121404ifrs-full:NoncontrollingInterestsMember2021-12-310001121404ifrs-full:RetainedEarningsMember2022-01-012022-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001121404ifrs-full:EquityAttributableToOwnersOfParentMember2022-01-012022-06-300001121404ifrs-full:NoncontrollingInterestsMember2022-01-012022-06-300001121404sny:EuroapiMember2022-01-012022-06-30xbrli:pure0001121404ifrs-full:TreasurySharesMember2022-01-012022-06-300001121404ifrs-full:IssuedCapitalMember2022-01-012022-06-300001121404ifrs-full:AdditionalPaidinCapitalMember2022-01-012022-06-300001121404ifrs-full:ReserveOfSharebasedPaymentsMember2022-01-012022-06-300001121404ifrs-full:IssuedCapitalMember2022-06-300001121404ifrs-full:AdditionalPaidinCapitalMember2022-06-300001121404ifrs-full:TreasurySharesMember2022-06-300001121404ifrs-full:RetainedEarningsMember2022-06-300001121404ifrs-full:ReserveOfSharebasedPaymentsMember2022-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-06-300001121404ifrs-full:EquityAttributableToOwnersOfParentMember2022-06-300001121404ifrs-full:NoncontrollingInterestsMember2022-06-300001121404sny:EuroapiMember2022-05-102022-05-100001121404sny:ConsumerHealthcareAndPharmaceuticalsMember2022-01-012022-06-30sny:activity0001121404sny:PharmaceuticalsMember2021-01-012021-06-300001121404sny:PharmaceuticalsMember2021-01-012021-12-310001121404sny:ConsumerHealthcareMember2021-01-012021-12-310001121404country:AR2022-06-300001121404country:TR2022-06-3000011214042022-06-13sny:trial0001121404sny:USGovernmentMembersny:CollaborationAgreementWithGSKMember2022-01-012022-06-300001121404sny:USGovernmentMembersny:CollaborationAgreementWithGSKMember2021-01-012021-12-310001121404sny:AmunixPharmaceuticalsIncMember2022-02-08iso4217:USD0001121404sny:AmunixPharmaceuticalsIncMember2022-02-082022-06-300001121404sny:EuroapiMember2022-03-172022-03-170001121404sny:EPICBPIFranceMembersny:EuroapiMember2022-03-170001121404sny:EPICBPIFranceMembersny:EuroapiMember2022-03-172022-03-170001121404sny:EuroapiMember2022-05-102022-06-300001121404sny:EuroapiMember2022-05-102022-05-100001121404sny:EuroapiMember2022-05-032022-05-030001121404sny:EuroapiMember2022-05-100001121404sny:EuroapiMember2021-01-012021-12-310001121404sny:EPICBPIFranceMembersny:EuroapiMember2022-06-172022-06-170001121404sny:EPICBPIFranceMembersny:EuroapiMember2022-06-170001121404sny:EuroapiMember2022-06-300001121404ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2022-05-100001121404sny:RegulatoryComplianceCostsMember2022-05-100001121404sny:EuroapiMembersny:ManufactureAndSupplyCollaborationAgreementMember2021-10-012021-10-010001121404sny:EuroapiMembersny:ManufactureAndSupplyCollaborationAgreementMember2021-10-010001121404sny:EuroapiMembersny:ManufactureAndSupplyCollaborationAgreementMember2022-06-300001121404sny:MajorCollaborationAgreementMembersny:ImmunoOncologyCollaborationAgreementMembersny:RegeneronPharmaceuticalsIncMember2022-07-012022-07-310001121404sny:ImmunoOncologyCollaborationAgreementMembersny:RegeneronPharmaceuticalsIncMember2022-06-012022-06-300001121404sny:RegeneronPharmaceuticalsIncMember2022-06-300001121404sny:AntibodiesCollaborationAgreementMembersny:RegeneronPharmaceuticalsIncMember2022-01-012022-05-310001121404sny:AntibodiesCollaborationAgreementMembersny:RegeneronPharmaceuticalsIncMember2022-06-012022-06-300001121404sny:AntibodiesCollaborationAgreementMembersny:RegeneronPharmaceuticalsIncMember2022-01-012022-06-300001121404sny:PharmaceuticalsMember2022-01-012022-06-300001121404sny:PharmaceuticalsMember2021-01-012021-12-310001121404sny:PharmaceuticalsMembersny:IndustrialFacilitiesMember2022-01-012022-06-300001121404sny:PharmaceuticalsMembersny:IndustrialFacilitiesMember2021-01-012021-12-310001121404sny:PharmaceuticalsMembersny:ResearchSitesMember2022-01-012022-06-300001121404sny:PharmaceuticalsMembersny:ResearchSitesMember2021-01-012021-12-310001121404sny:PharmaceuticalsMembersny:OtherMember2022-01-012022-06-300001121404sny:PharmaceuticalsMembersny:OtherMember2021-01-012021-12-310001121404sny:VaccinesMember2022-01-012022-06-300001121404sny:VaccinesMember2021-01-012021-12-310001121404sny:ConsumerHealthcareMember2022-01-012022-06-300001121404sny:ConsumerHealthcareMember2021-01-012021-12-310001121404sny:AcquiredRAndDMemberifrs-full:GrossCarryingAmountMember2021-12-310001121404sny:MarketedProductsTrademarksAndOtherRightsMemberifrs-full:GrossCarryingAmountMember2021-12-310001121404ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2021-12-310001121404ifrs-full:GrossCarryingAmountMember2021-12-310001121404sny:AcquiredRAndDMemberifrs-full:GrossCarryingAmountMember2022-01-012022-06-300001121404sny:MarketedProductsTrademarksAndOtherRightsMemberifrs-full:GrossCarryingAmountMember2022-01-012022-06-300001121404ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2022-01-012022-06-300001121404ifrs-full:GrossCarryingAmountMember2022-01-012022-06-300001121404sny:AcquiredRAndDMemberifrs-full:GrossCarryingAmountMember2022-06-300001121404sny:MarketedProductsTrademarksAndOtherRightsMemberifrs-full:GrossCarryingAmountMember2022-06-300001121404ifrs-full:ComputerSoftwareMemberifrs-full:GrossCarryingAmountMember2022-06-300001121404ifrs-full:GrossCarryingAmountMember2022-06-300001121404sny:AcquiredRAndDMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404sny:MarketedProductsTrademarksAndOtherRightsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404ifrs-full:ComputerSoftwareMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001121404sny:AcquiredRAndDMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404sny:MarketedProductsTrademarksAndOtherRightsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404ifrs-full:ComputerSoftwareMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404sny:AcquiredRAndDMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404sny:MarketedProductsTrademarksAndOtherRightsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404ifrs-full:ComputerSoftwareMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404sny:AcquiredRAndDMember2021-12-310001121404sny:MarketedProductsTrademarksAndOtherRightsMember2021-12-310001121404ifrs-full:ComputerSoftwareMember2021-12-310001121404sny:AcquiredRAndDMember2022-06-300001121404sny:MarketedProductsTrademarksAndOtherRightsMember2022-06-300001121404ifrs-full:ComputerSoftwareMember2022-06-300001121404sny:AmunixPharmaceuticalsIncMembersny:MarketedProductsTrademarksAndOtherRightsMemberifrs-full:GrossCarryingAmountMember2022-01-012022-06-300001121404sny:LibtayoMemberifrs-full:NoncurrentAssetsHeldForSaleMemberifrs-full:GrossCarryingAmountMember2022-06-300001121404sny:LibtayoMemberifrs-full:NoncurrentAssetsHeldForSaleMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-06-300001121404sny:EnjaymoMember2022-01-012022-06-300001121404sny:EnjaymoMemberifrs-full:GrossCarryingAmountMember2022-01-012022-06-300001121404sny:EnjaymoMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-01-012022-06-300001121404sny:TechnologicalPlatformsMember2022-01-012022-06-300001121404sny:OtherIntangibleAssetsExcludingSoftwareMember2022-01-012022-06-300001121404sny:MarketedProductsMember2022-06-300001121404sny:MarketedProductsMember2021-12-310001121404sny:MarketedProductsMember2022-01-012022-06-300001121404sny:TechnologicalPlatformsMember2022-06-300001121404sny:TechnologicalPlatformsMember2021-12-310001121404sny:EuroapiMember2022-01-012022-06-300001121404sny:EuroapiMember2021-12-310001121404sny:InfraservGmbhAndCoHochstKGMember2022-01-012022-06-300001121404sny:InfraservGmbhAndCoHochstKGMember2022-06-300001121404sny:InfraservGmbhAndCoHochstKGMember2021-12-310001121404sny:MSPVaccineCompanyMember2022-01-012022-06-300001121404sny:MSPVaccineCompanyMember2022-06-300001121404sny:MSPVaccineCompanyMember2021-12-310001121404ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2022-01-012022-06-300001121404ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2022-06-300001121404ifrs-full:AggregatedIndividuallyImmaterialAssociatesMember2021-12-310001121404sny:MCMVaccineBVMembersny:MSPVaccineCompanyMember2022-01-012022-06-300001121404sny:AssociatesAndJointVenturesMember2022-01-012022-06-300001121404sny:AssociatesAndJointVenturesMember2021-01-012021-06-300001121404sny:AssociatesAndJointVenturesMember2021-01-012021-12-310001121404sny:AssociatesAndJointVenturesMember2022-06-300001121404sny:AssociatesAndJointVenturesMember2021-06-300001121404sny:AssociatesAndJointVenturesMember2021-12-310001121404ifrs-full:TradingEquitySecuritiesMember2022-06-300001121404ifrs-full:TradingEquitySecuritiesMember2021-12-310001121404ifrs-full:DebtSecuritiesMember2022-06-300001121404ifrs-full:DebtSecuritiesMember2021-12-310001121404sny:ExscientiaMember2022-01-072022-01-070001121404sny:IGMBiosciencesIncMember2022-03-292022-03-290001121404ifrs-full:AllowanceForCreditLossesMember2022-06-300001121404ifrs-full:AllowanceForCreditLossesMember2021-12-310001121404ifrs-full:NotLaterThanOneMonthMember2022-06-300001121404ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2022-06-300001121404ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2022-06-300001121404ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2022-06-300001121404ifrs-full:LaterThanOneYearMember2022-06-300001121404ifrs-full:NotLaterThanOneMonthMember2021-12-310001121404ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2021-12-310001121404ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember2021-12-310001121404ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember2021-12-310001121404ifrs-full:LaterThanOneYearMember2021-12-310001121404ifrs-full:IssuedCapitalMembersny:SanofiMember2022-01-012022-06-300001121404sny:ShareRepurchase2021ProgramMember2021-04-302021-04-300001121404sny:ShareRepurchase2021ProgramMember2021-01-012021-06-300001121404sny:ShareRepurchase2021ProgramMember2021-06-300001121404sny:ShareRepurchase2022ProgramMember2022-05-032022-05-030001121404sny:RestrictedSharePlan2022Member2022-01-012022-06-300001121404sny:RestrictedSharePlan2022Membersny:WithoutMarketConditionMember2022-01-012022-06-300001121404sny:WithMarketConditionMembersny:RestrictedSharePlan2022Member2022-01-012022-06-300001121404sny:WithMarketConditionMembersny:RestrictedSharePlan2022Membersny:ExcludingChiefExecutiveOfficerMember2022-01-012022-06-300001121404sny:WithMarketConditionMembersny:RestrictedSharePlan2022AdditionalSharesMembersny:ExcludingChiefExecutiveOfficerMember2022-01-012022-06-300001121404sny:WithMarketConditionMembersny:RestrictedSharePlan2022Membersrt:ChiefExecutiveOfficerMember2022-01-012022-06-300001121404sny:RestrictedSharesMember2022-01-012022-06-300001121404sny:RestrictedSharesMember2021-01-012021-06-300001121404sny:RestrictedSharesMember2022-06-300001121404sny:RestrictedSharesMember2021-06-300001121404sny:RestrictedSharePlan2022Member2022-06-300001121404sny:RestrictedSharePlan2022Member2021-06-300001121404sny:RestrictedSharePlan2021Member2022-06-300001121404sny:RestrictedSharePlan2021Member2021-06-300001121404sny:RestrictedSharePlan2020Member2022-06-300001121404sny:RestrictedSharePlan2020Member2021-06-300001121404sny:RestrictedSharePlan2019Member2022-06-300001121404sny:RestrictedSharePlan2019Member2021-06-300001121404sny:RestrictedSharePlan2018Member2022-06-300001121404sny:RestrictedSharePlan2018Member2021-06-300001121404sny:EmployeeShareOwnershipPlanMember2022-02-030001121404sny:EmployeeShareOwnershipPlanMember2022-06-290001121404sny:EmployeeShareOwnershipPlanMember2022-01-012022-06-300001121404sny:EmployeeShareOwnershipPlanMember2021-02-040001121404sny:EmployeeShareOwnershipPlanMember2021-06-250001121404sny:EmployeeShareOwnershipPlanMember2021-01-012021-06-300001121404ifrs-full:BottomOfRangeMembersny:StockOptionPlanMembersny:ExercisePriceRangeTwoMember2022-06-300001121404sny:StockOptionPlanMemberifrs-full:TopOfRangeMembersny:ExercisePriceRangeTwoMember2022-06-300001121404sny:StockOptionPlanMembersny:ExercisePriceRangeTwoMember2022-06-300001121404sny:StockOptionPlanMembersny:ExercisePriceRangeTwoMember2022-01-012022-06-300001121404ifrs-full:BottomOfRangeMembersny:StockOptionPlanMembersny:ExercisePriceRangeThreeMember2022-06-300001121404sny:StockOptionPlanMemberifrs-full:TopOfRangeMembersny:ExercisePriceRangeThreeMember2022-06-300001121404sny:StockOptionPlanMembersny:ExercisePriceRangeThreeMember2022-06-300001121404sny:StockOptionPlanMembersny:ExercisePriceRangeThreeMember2022-01-012022-06-300001121404sny:ExercisePriceRangeFourMemberifrs-full:BottomOfRangeMembersny:StockOptionPlanMember2022-06-300001121404sny:ExercisePriceRangeFourMembersny:StockOptionPlanMemberifrs-full:TopOfRangeMember2022-06-300001121404sny:ExercisePriceRangeFourMembersny:StockOptionPlanMember2022-06-300001121404sny:ExercisePriceRangeFourMembersny:StockOptionPlanMember2022-01-012022-06-300001121404sny:StockOptionPlanMember2022-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:EquityInstrumentsIncludedInFinancialAssetsMembersny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:EquityInstrumentsIncludedInFinancialAssetsMembersny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:EquityInstrumentsIncludedInFinancialAssetsMembersny:ItemsNotSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsSubsequentlyReclassifiableToProfitOrLossMembersny:DebtInstrumentsMember2022-01-012022-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsSubsequentlyReclassifiableToProfitOrLossMembersny:DebtInstrumentsMember2021-01-012021-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsSubsequentlyReclassifiableToProfitOrLossMembersny:DebtInstrumentsMember2021-01-012021-12-310001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404ifrs-full:AccumulatedOtherComprehensiveIncomeMembersny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404sny:ItemsSubsequentlyReclassifiableToProfitOrLossMembersny:DebtInstrumentsMember2022-01-012022-06-300001121404sny:ItemsSubsequentlyReclassifiableToProfitOrLossMembersny:DebtInstrumentsMember2021-01-012021-12-310001121404sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2022-01-012022-06-300001121404sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-12-310001121404sny:ItemsSubsequentlyReclassifiableToProfitOrLossMember2021-01-012021-06-300001121404sny:AmortizedCostNettingMember2022-06-300001121404sny:AdjustmentToDebtMeasuredAtFairValueMember2022-06-300001121404sny:ValueOnRedemptionMember2022-06-300001121404sny:ValueOnRedemptionMember2021-12-310001121404sny:NonCurrentLiabilitiesMembersny:ValueOnRedemptionMember2022-06-300001121404sny:ValueOnRedemptionMembersny:CurrentLiabilitiesMember2022-06-300001121404sny:NonCurrentLiabilitiesMembersny:ValueOnRedemptionMember2021-12-310001121404sny:ValueOnRedemptionMembersny:CurrentLiabilitiesMember2021-12-310001121404sny:ValueOnRedemptionMembersny:NonCurrentAssetsMember2022-06-300001121404sny:ValueOnRedemptionMembersny:CurrentAssetsMember2022-06-300001121404sny:ValueOnRedemptionMembersny:NonCurrentAssetsMember2021-12-310001121404sny:ValueOnRedemptionMembersny:CurrentAssetsMember2021-12-310001121404sny:OneBillionFiveHundredMillionBondsIssuedInApril2022Member2022-04-30sny:tranche0001121404sny:EightHundredAndFiftyMillionOfFixedRateBondsMaturingAprilTwoThousandTwentyFiveMember2022-04-300001121404sny:SixHundredAndFiftyMillionOfFixedRateBondsMaturingAprilTwoThousandTwentyNineMember2022-04-30sny:patientsny:Countrysny:bond0001121404sny:OneBillionBondsMaturingJanuary2022Member2014-09-300001121404sny:EightHundredFiftyMillionBondsMaturingFebruary2022Member2019-03-310001121404sny:EightHundredFiftyMillionBondsMaturingJune2022Member2016-09-300001121404sny:SyndicatedCreditFacilityOneMember2022-06-300001121404sny:SyndicatedCreditFacilityTwoMember2022-06-300001121404sny:SyndicatedCreditFacilityTwoMember2022-01-012022-06-300001121404sny:CommercialPaperProgramInFranceMember2022-06-300001121404sny:CommercialPaperProgramInUSAMember2022-06-300001121404sny:CommercialPaperProgramInUSAMember2022-01-012022-06-300001121404sny:AtMarketValueMember2022-06-300001121404sny:AtMarketValueMember2021-12-310001121404sny:ValueOnRedemptionMember2022-01-012022-06-300001121404sny:ValueOnRedemptionMember2021-01-012021-12-310001121404sny:ForwardCurrencySalesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesMember2022-06-300001121404sny:ForwardCurrencySalesMemberifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesMemberifrs-full:CashFlowHedgesMember2022-06-300001121404sny:ForwardCurrencySalesMemberifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:ForwardCurrencySalesMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:ForwardCurrencySalesInUSDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInUSDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInUSDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInUSDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencySalesInUSDollarMember2022-06-300001121404sny:ForwardCurrencySalesInUSDollarMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInUSDollarMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:AtNotionalAmountMembersny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMembersny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404sny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMembersny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404ifrs-full:AtFairValueMembersny:NotEligibleForHedgeAccountingMembersny:ForwardCurrencySalesInChineseYuanRenminbiMember2022-06-300001121404sny:ForwardCurrencySalesInSingaporeDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInSingaporeDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404sny:ForwardCurrencySalesInSingaporeDollarMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInSingaporeDollarMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:ForwardCurrencySalesInJapaneseYenMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInJapaneseYenMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInJapaneseYenMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInJapaneseYenMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInJapaneseYenMembersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:ForwardCurrencySalesInJapaneseYenMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInJapaneseYenMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:ForwardCurrencySalesInKoreanWonMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInKoreanWonMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInKoreanWonMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInKoreanWonMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInKoreanWonMembersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:ForwardCurrencySalesInKoreanWonMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencySalesInKoreanWonMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:ForwardCurrencyPurchasesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencyPurchasesMember2022-06-300001121404sny:ForwardCurrencyPurchasesMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:ForwardCurrencyPurchasesInUSDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInUSDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInUSDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInUSDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencyPurchasesInUSDollarMember2022-06-300001121404sny:ForwardCurrencyPurchasesInUSDollarMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInUSDollarMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:ForwardCurrencyPurchasesInSingaporeDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInSingaporeDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404sny:ForwardCurrencyPurchasesInSingaporeDollarMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInSingaporeDollarMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:ForwardCurrencyPurchasesInKoreanWonMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInKoreanWonMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInKoreanWonMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInKoreanWonMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencyPurchasesInKoreanWonMember2022-06-300001121404sny:ForwardCurrencyPurchasesInKoreanWonMembersny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInKoreanWonMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404sny:AtNotionalAmountMembersny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMembersny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404sny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMembersny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404ifrs-full:AtFairValueMembersny:NotEligibleForHedgeAccountingMembersny:ForwardCurrencyPurchasesInCanadianDollarMember2022-06-300001121404sny:AtNotionalAmountMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404ifrs-full:AtFairValueMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404sny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404ifrs-full:AtFairValueMembersny:NotEligibleForHedgeAccountingMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404sny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:NotEligibleForHedgeAccountingMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:NotEligibleForHedgeAccountingMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ForwardCurrencySalesInUSDollarMember2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:ForwardCurrencySalesInUSDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:NotLaterThanOneYearMembersny:ForwardCurrencySalesInUSDollarMember2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:ForwardCurrencySalesInSingaporeDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:NotLaterThanOneYearMembersny:ForwardCurrencySalesInSingaporeDollarMember2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMembersny:ForwardCurrencySalesInPoundSterlingMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:NotLaterThanOneYearMembersny:ForwardCurrencySalesInPoundSterlingMember2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:ForwardCurrencyPurchasesInUSDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:ForwardCurrencyPurchasesInUSDollarMember2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:ForwardCurrencyPurchasesInSingaporeDollarMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:NotLaterThanOneYearMembersny:ForwardCurrencyPurchasesInJapaneseYenMember2022-06-300001121404sny:ForwardCurrencySalesInUSDollarMember2022-06-300001121404sny:ForwardCurrencySalesInSingaporeDollarMember2022-06-30iso4217:SGD0001121404sny:ForwardCurrencyPurchasesInUSDollarUSBondMember2022-06-300001121404sny:ForwardCurrencyPurchasesInUSDollarUSBondMember2022-01-012022-06-300001121404sny:ForwardCurrencyPurchasesInUSDollarIntragroupAccountMember2022-06-300001121404sny:ForwardCurrencyPurchasesInUSDollarIntragroupAccountMember2022-01-012022-06-300001121404sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-06-300001121404sny:ForwardCurrencyPurchasesInSingaporeDollarMember2022-01-012022-06-300001121404sny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404sny:AtNotionalAmountMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404sny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:FairValueHedgesMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:FairValueHedgesMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:InterestRateSwapsPayCapitalizedEsterReceive006Member2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMembersny:AtNotionalAmountMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:AtFairValueMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:FairValueHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:FairValueHedgesMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:CashFlowHedgesMember2022-06-300001121404sny:InterestRateSwapsPay057ReceiveCapitalizedEsterMemberifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Membersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Membersny:AtNotionalAmountMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Membersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Member2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:FairValueHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:FairValueHedgesMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:CashFlowHedgesMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive103Memberifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Member2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Membersny:AtNotionalAmountMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Membersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:AtFairValueMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:FairValueHedgesMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:AtFairValueMemberifrs-full:FairValueHedgesMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedSOFRUSDReceive132Memberifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Membersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Membersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedEsterReceive069Memberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedEsterReceive069Membersny:AtNotionalAmountMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Membersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedEsterReceive069Membersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404sny:InterestRateSwapsPayCapitalizedEsterReceive069Memberifrs-full:FairValueHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Memberifrs-full:FairValueHedgesMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Membersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Member2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:InterestRateSwapsPayCapitalizedEsterReceive069Membersny:ValueOfHedgeRecognizedInEquityMember2022-06-300001121404sny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404sny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Memberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404sny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:FairValueHedgesMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:FairValueHedgesMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:AtNotionalAmountMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:InterestRateSwapsPayCapitalizedEsterReceive092Member2022-06-300001121404sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Membersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Membersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Memberifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Membersny:AtNotionalAmountMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Membersny:AtNotionalAmountMember2022-06-300001121404sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Membersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404sny:InterestRateSwapsReceiveCapitalizedEoniaPay158Memberifrs-full:FairValueHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Memberifrs-full:FairValueHedgesMember2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Membersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:CashFlowHedgesMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404ifrs-full:CashFlowHedgesMembersny:ValueOfHedgeRecognizedInEquityMembersny:InterestRateSwapsReceiveCapitalizedEoniaPay158Member2022-06-300001121404ifrs-full:NotLaterThanOneYearMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMembersny:AtNotionalAmountMember2022-06-300001121404sny:AtNotionalAmountMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2022-06-300001121404ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:FairValueHedgesMembersny:AtNotionalAmountMember2022-06-300001121404ifrs-full:AtFairValueMemberifrs-full:FairValueHedgesMember2022-06-300001121404sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2021-12-310001121404sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2021-12-310001121404sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2021-12-310001121404sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2021-12-310001121404sny:OtherLiabilities1Member2021-12-310001121404sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-01-012022-06-300001121404sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2022-01-012022-06-300001121404sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2022-01-012022-06-300001121404sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2022-01-012022-06-300001121404sny:OtherLiabilities1Member2022-01-012022-06-300001121404sny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-06-300001121404sny:MSDContingentConsiderationEuropeanVaccinesBusinessMember2022-06-300001121404sny:ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember2022-06-300001121404sny:ContingentConsiderationArisingFromAcquisitionOfAmunixMember2022-06-300001121404sny:OtherLiabilities1Member2022-06-300001121404ifrs-full:TopOfRangeMembersny:BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember2022-01-012022-06-300001121404sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2021-12-310001121404sny:ProvisionsForOtherLongTermBenefitsMember2021-12-310001121404sny:NonCurrentRestructuringProvisionMember2021-12-310001121404ifrs-full:MiscellaneousOtherProvisionsMember2021-12-310001121404sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2022-01-012022-06-300001121404sny:ProvisionsForOtherLongTermBenefitsMember2022-01-012022-06-300001121404sny:NonCurrentRestructuringProvisionMember2022-01-012022-06-300001121404ifrs-full:MiscellaneousOtherProvisionsMember2022-01-012022-06-300001121404sny:ProvisionsForPensionsAndOtherPostemploymentBenefitsMember2022-06-300001121404sny:ProvisionsForOtherLongTermBenefitsMember2022-06-300001121404sny:NonCurrentRestructuringProvisionMember2022-06-300001121404ifrs-full:MiscellaneousOtherProvisionsMember2022-06-300001121404sny:PensionsAndOtherPostEmploymentBenefitsMemberifrs-full:PlanAssetsMember2022-01-012022-06-300001121404sny:PensionsAndOtherPostEmploymentBenefitsMemberifrs-full:PlanAssetsMember2021-01-012021-06-300001121404sny:PensionsAndOtherPostEmploymentBenefitsMemberifrs-full:PlanAssetsMember2021-01-012021-12-310001121404sny:PensionsAndOtherPostEmploymentBenefitsMember2022-01-012022-06-300001121404sny:PensionsAndOtherPostEmploymentBenefitsMember2021-01-012021-06-300001121404sny:PensionsAndOtherPostEmploymentBenefitsMember2021-01-012021-12-310001121404ifrs-full:ActuarialAssumptionOfDiscountRatesMembersrt:MinimumMember2022-06-300001121404ifrs-full:ActuarialAssumptionOfDiscountRatesMembersrt:MaximumMember2022-06-300001121404country:GBifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2022-06-300001121404ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMembersny:EUROZONEMember2022-06-300001121404ifrs-full:ActuarialAssumptionOfDiscountRatesMembersrt:MaximumMember2021-06-300001121404ifrs-full:ActuarialAssumptionOfDiscountRatesMembersrt:MinimumMember2021-06-300001121404country:GBifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2021-06-300001121404ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMembersny:EUROZONEMember2021-06-300001121404sny:ExscientiaMembersrt:MaximumMember2022-01-07sny:molecule0001121404sny:ABLBioMember2022-01-112022-01-110001121404sny:ABLBioMembersrt:MaximumMember2022-01-110001121404sny:AdageneIncMember2022-03-022022-03-020001121404sny:AdageneIncMembersrt:MaximumMember2022-03-020001121404sny:AntibodiesCollaborationAgreementMembersny:BlackstoneLifeSciencesMember2022-03-152022-03-150001121404sny:IGMBiosciencesIncMembersrt:MaximumMember2022-03-29sny:target0001121404sny:ProductLiabilitiesMembersny:ActionForWhichWeAreDefendantMembersny:ZantacProductLitigationInTheUSMember2022-06-300001121404sny:ProductLiabilitiesMembersny:ActionForWhichWeAreDefendantMembersny:DepakineProductLitigationInFranceMember2022-05-120001121404sny:ProductLiabilitiesMembersny:ActionForWhichWeAreDefendantMembersny:DepakineProductLitigationInFranceMember2022-05-122022-05-120001121404sny:DepakineProductLitigationInSpainMembersny:ProductLiabilitiesMembersny:ActionForWhichWeAreDefendantMember2022-03-17sny:claimant0001121404sny:DepakineProductLitigationInSpainMembersny:ProductLiabilitiesMembersny:ActionForWhichWeAreDefendantMember2022-03-172022-03-170001121404sny:OtherOperatingIncomeExpenseMemberifrs-full:OtherRelatedPartiesMember2022-01-012022-06-300001121404sny:OtherOperatingIncomeExpenseMemberifrs-full:OtherRelatedPartiesMember2021-01-012021-06-300001121404sny:OtherOperatingIncomeExpenseMembersny:RegeneronMember2022-01-012022-06-300001121404sny:OtherOperatingIncomeExpenseMembersny:RegeneronMember2021-01-012021-06-300001121404sny:DaiichiSankyoMembersny:OtherOperatingIncomeExpenseMember2021-01-012021-06-300001121404sny:CommercializationRelatedExpensesMembersny:RegeneronMemberifrs-full:OtherRelatedPartiesMember2022-01-012022-06-300001121404sny:CommercializationRelatedExpensesMembersny:RegeneronMemberifrs-full:OtherRelatedPartiesMember2021-01-012021-06-300001121404sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMembersny:AntibodiesAllianceMember2022-01-012022-06-300001121404sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMembersny:AntibodiesAllianceMember2021-01-012021-06-300001121404sny:ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMembersny:AntibodiesAllianceMember2021-01-012021-12-310001121404sny:AntibodiesAllianceMembersny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2022-01-012022-06-300001121404sny:AntibodiesAllianceMembersny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2021-01-012021-06-300001121404sny:AntibodiesAllianceMembersny:ShareOfProfitOrLossFromCommercializationOfZaltrapMember2021-01-012021-12-310001121404sny:AntibodiesAllianceMembersny:CommercializationRelatedExpensesMember2022-01-012022-06-300001121404sny:AntibodiesAllianceMembersny:CommercializationRelatedExpensesMember2021-01-012021-06-300001121404sny:AntibodiesAllianceMembersny:CommercializationRelatedExpensesMember2021-01-012021-12-310001121404sny:AntibodiesAllianceMember2022-01-012022-06-300001121404sny:AntibodiesAllianceMember2021-01-012021-06-300001121404sny:AntibodiesAllianceMember2021-01-012021-12-310001121404sny:ImmunoOncologyAllianceMember2022-01-012022-06-300001121404sny:ImmunoOncologyAllianceMember2021-01-012021-06-300001121404sny:ImmunoOncologyAllianceMember2021-01-012021-12-310001121404sny:OthersCounterpartyMember2022-01-012022-06-300001121404sny:OthersCounterpartyMember2021-01-012021-06-300001121404sny:OthersCounterpartyMember2021-01-012021-12-310001121404sny:OtherOperatingIncomeExpenseMembersny:RegeneronMember2021-01-012021-12-3100011214042021-07-012022-06-300001121404sny:InterestRateAndCurrencyDerivativesMember2022-01-012022-06-300001121404sny:InterestRateAndCurrencyDerivativesMember2021-01-012021-06-300001121404sny:InterestRateAndCurrencyDerivativesMember2021-01-012021-12-31sny:segment0001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:GeneralMedicineMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2022-01-012022-06-300001121404country:USsny:GeneralMedicineMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:GeneralMedicineMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:GeneralMedicineMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:GeneralMedicineMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2021-01-012021-06-300001121404country:USsny:GeneralMedicineMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:GeneralMedicineMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:GeneralMedicineMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:LantusMembersrt:EuropeMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:LantusMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:LantusMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:LantusMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:LantusMembersrt:EuropeMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:LantusMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:LantusMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:LantusMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:ToujeoMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:ToujeoMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:ToujeoMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:ToujeoMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:ToujeoMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:ToujeoMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:ToujeoMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:ToujeoMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:PraluentMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:PraluentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:PraluentMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:PraluentMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:PraluentMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:PraluentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:PraluentMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:PraluentMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:MultaqMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:MultaqMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:MultaqMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:MultaqMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:MultaqMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:MultaqMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:MultaqMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:MultaqMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:LovenoxMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:LovenoxMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:LovenoxMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:LovenoxMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:LovenoxMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:LovenoxMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:LovenoxMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:LovenoxMember2021-01-012021-06-300001121404sny:PlavixMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2022-01-012022-06-300001121404country:USsny:PlavixMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PlavixMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:PlavixMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:PlavixMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2021-01-012021-06-300001121404country:USsny:PlavixMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PlavixMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:PlavixMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:ThymoglobulinMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:ThymoglobulinMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:ThymoglobulinMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:ThymoglobulinMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:ThymoglobulinMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:ThymoglobulinMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:ThymoglobulinMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:ThymoglobulinMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:IndustrialSalesMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:IndustrialSalesMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:IndustrialSalesMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:IndustrialSalesMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:IndustrialSalesMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:IndustrialSalesMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:IndustrialSalesMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:IndustrialSalesMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:SpecialtyCareMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:SpecialtyCareMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:SpecialtyCareMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:SpecialtyCareMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:SpecialtyCareMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:SpecialtyCareMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:SpecialtyCareMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:SpecialtyCareMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:AubagioMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:AubagioMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:AubagioMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:AubagioMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:AubagioMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:AubagioMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:AubagioMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:AubagioMember2021-01-012021-06-300001121404sny:CerezymeMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2022-01-012022-06-300001121404country:USsny:CerezymeMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:CerezymeMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:CerezymeMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:CerezymeMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2021-01-012021-06-300001121404country:USsny:CerezymeMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:CerezymeMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:CerezymeMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:MyozymeOrLumizymeMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:MyozymeOrLumizymeMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:MyozymeOrLumizymeMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:MyozymeOrLumizymeMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:MyozymeOrLumizymeMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:MyozymeOrLumizymeMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:MyozymeOrLumizymeMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:MyozymeOrLumizymeMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:FabrazymeMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:FabrazymeMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:FabrazymeMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:FabrazymeMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:FabrazymeMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:FabrazymeMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:FabrazymeMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:FabrazymeMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:EloctateMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:EloctateMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:EloctateMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:EloctateMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:EloctateMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:EloctateMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:EloctateMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:EloctateMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:JevtanaMember2022-01-012022-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:JevtanaMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:JevtanaMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersny:JevtanaMember2022-01-012022-06-300001121404sny:PharmaceuticalsSegmentMembersrt:EuropeMembersny:JevtanaMember2021-01-012021-06-300001121404country:USsny:PharmaceuticalsSegmentMembersny:JevtanaMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PharmaceuticalsSegmentMembersny:JevtanaMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMembersny:JevtanaMember2021-01-012021-06-300001121404sny:DupixentMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2022-01-012022-06-300001121404country:USsny:DupixentMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:DupixentMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:DupixentMembersny:PharmaceuticalsSegmentMember2022-01-012022-06-300001121404sny:DupixentMembersny:PharmaceuticalsSegmentMembersrt:EuropeMember2021-01-012021-06-300001121404country:USsny:DupixentMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:DupixentMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:DupixentMembersny:PharmaceuticalsSegmentMember2021-01-012021-06-300001121404sny:VaccinesSegmentMembersrt:EuropeMember2022-01-012022-06-300001121404country:USsny:VaccinesSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:VaccinesSegmentMember2022-01-012022-06-300001121404sny:VaccinesSegmentMember2022-01-012022-06-300001121404sny:VaccinesSegmentMembersrt:EuropeMember2021-01-012021-06-300001121404country:USsny:VaccinesSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:VaccinesSegmentMember2021-01-012021-06-300001121404sny:VaccinesSegmentMember2021-01-012021-06-300001121404sny:VaccinesSegmentMembersrt:EuropeMembersny:PolioPertussisHibVaccinesMember2022-01-012022-06-300001121404country:USsny:VaccinesSegmentMembersny:PolioPertussisHibVaccinesMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:VaccinesSegmentMembersny:PolioPertussisHibVaccinesMember2022-01-012022-06-300001121404sny:VaccinesSegmentMembersny:PolioPertussisHibVaccinesMember2022-01-012022-06-300001121404sny:VaccinesSegmentMembersrt:EuropeMembersny:PolioPertussisHibVaccinesMember2021-01-012021-06-300001121404country:USsny:VaccinesSegmentMembersny:PolioPertussisHibVaccinesMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:VaccinesSegmentMembersny:PolioPertussisHibVaccinesMember2021-01-012021-06-300001121404sny:VaccinesSegmentMembersny:PolioPertussisHibVaccinesMember2021-01-012021-06-300001121404sny:VaccinesSegmentMembersrt:EuropeMembersny:InfluenzaVaccinesMember2022-01-012022-06-300001121404country:USsny:VaccinesSegmentMembersny:InfluenzaVaccinesMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:VaccinesSegmentMembersny:InfluenzaVaccinesMember2022-01-012022-06-300001121404sny:VaccinesSegmentMembersny:InfluenzaVaccinesMember2022-01-012022-06-300001121404sny:VaccinesSegmentMembersrt:EuropeMembersny:InfluenzaVaccinesMember2021-01-012021-06-300001121404country:USsny:VaccinesSegmentMembersny:InfluenzaVaccinesMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:VaccinesSegmentMembersny:InfluenzaVaccinesMember2021-01-012021-06-300001121404sny:VaccinesSegmentMembersny:InfluenzaVaccinesMember2021-01-012021-06-300001121404srt:EuropeMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404country:USsny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404srt:EuropeMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404country:USsny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:AllergyMembersrt:EuropeMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404country:USsny:AllergyMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:AllergyMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:AllergyMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:AllergyMembersrt:EuropeMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404country:USsny:AllergyMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:AllergyMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:AllergyMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404srt:EuropeMembersny:PainCareMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404country:USsny:PainCareMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:PainCareMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:PainCareMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404srt:EuropeMembersny:PainCareMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404country:USsny:PainCareMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:PainCareMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:PainCareMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:DigestiveWellnessMembersrt:EuropeMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404country:USsny:DigestiveWellnessMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:OtherCountriesMembersny:DigestiveWellnessMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:DigestiveWellnessMembersny:ConsumerHealthcareSegmentMember2022-01-012022-06-300001121404sny:DigestiveWellnessMembersrt:EuropeMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404country:USsny:DigestiveWellnessMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:OtherCountriesMembersny:DigestiveWellnessMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404sny:DigestiveWellnessMembersny:ConsumerHealthcareSegmentMember2021-01-012021-06-300001121404srt:EuropeMember2022-01-012022-06-300001121404country:US2022-01-012022-06-300001121404sny:OtherCountriesMember2022-01-012022-06-300001121404srt:EuropeMember2021-01-012021-06-300001121404country:US2021-01-012021-06-300001121404sny:OtherCountriesMember2021-01-012021-06-300001121404ifrs-full:AllOtherSegmentsMember2022-01-012022-06-300001121404ifrs-full:ReportableSegmentsMember2022-01-012022-06-300001121404ifrs-full:AllOtherSegmentsMember2021-01-012021-06-300001121404ifrs-full:ReportableSegmentsMember2021-01-012021-06-300001121404sny:PharmaceuticalsSegmentMember2021-01-012021-12-310001121404sny:VaccinesSegmentMember2021-01-012021-12-310001121404sny:ConsumerHealthcareSegmentMember2021-01-012021-12-310001121404ifrs-full:AllOtherSegmentsMember2021-01-012021-12-310001121404ifrs-full:ReportableSegmentsMember2021-01-012021-12-310001121404ifrs-full:OperatingSegmentsMember2022-01-012022-06-300001121404ifrs-full:OperatingSegmentsMember2021-01-012021-06-300001121404ifrs-full:OperatingSegmentsMember2021-01-012021-12-310001121404ifrs-full:MaterialReconcilingItemsMember2022-01-012022-06-300001121404ifrs-full:MaterialReconcilingItemsMember2021-01-012021-06-300001121404ifrs-full:MaterialReconcilingItemsMember2021-01-012021-12-310001121404sny:PharmaceuticalsMember2022-06-300001121404sny:VaccinesMember2022-06-300001121404sny:ConsumerHealthcareSegmentMember2022-06-300001121404ifrs-full:ReportableSegmentsMember2022-06-300001121404sny:PharmaceuticalsMember2021-06-300001121404sny:VaccinesMember2021-06-300001121404sny:ConsumerHealthcareSegmentMember2021-06-300001121404ifrs-full:ReportableSegmentsMember2021-06-300001121404sny:PharmaceuticalsMember2021-01-012021-06-300001121404sny:VaccinesMember2021-01-012021-06-300001121404sny:PharmaceuticalsMember2021-12-310001121404sny:VaccinesMember2021-12-310001121404sny:ConsumerHealthcareSegmentMember2021-12-310001121404ifrs-full:ReportableSegmentsMember2021-12-310001121404sny:ReportableGeographicalZonesMember2022-01-012022-06-300001121404country:FR2022-01-012022-06-300001121404srt:NorthAmericaMember2022-01-012022-06-300001121404sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2022-01-012022-06-300001121404sny:ReportableGeographicalZonesMember2022-06-300001121404srt:EuropeMember2022-06-300001121404country:FR2022-06-300001121404srt:NorthAmericaMember2022-06-300001121404country:US2022-06-300001121404sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2022-06-300001121404sny:ReportableGeographicalZonesMember2021-01-012021-06-300001121404country:FR2021-01-012021-06-300001121404srt:NorthAmericaMember2021-01-012021-06-300001121404sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-01-012021-06-300001121404sny:ReportableGeographicalZonesMember2021-06-300001121404srt:EuropeMember2021-06-300001121404country:FR2021-06-300001121404srt:NorthAmericaMember2021-06-300001121404country:US2021-06-300001121404sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-06-300001121404sny:ReportableGeographicalZonesMember2021-01-012021-12-310001121404srt:EuropeMember2021-01-012021-12-310001121404country:FR2021-01-012021-12-310001121404srt:NorthAmericaMember2021-01-012021-12-310001121404country:US2021-01-012021-12-310001121404sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-01-012021-12-310001121404sny:ReportableGeographicalZonesMember2021-12-310001121404srt:EuropeMember2021-12-310001121404country:FR2021-12-310001121404srt:NorthAmericaMember2021-12-310001121404country:US2021-12-310001121404sny:OtherCountriesExcludingEuropeAndNorthAmericaMember2021-12-310001121404sny:CertainWholesalersInTheUnitedStatesMember2022-01-012022-06-300001121404sny:CustomerOneMember2022-01-012022-06-300001121404sny:CustomerTwoMember2022-01-012022-06-300001121404sny:CustomerThreeMember2022-01-012022-06-300001121404sny:CustomerOneMember2021-01-012021-06-300001121404sny:CustomerTwoMember2021-01-012021-06-300001121404sny:CustomerThreeMember2021-01-012021-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2022
Commission File Number: 001-31368
 
 
SANOFI
(Translation of registrant’s name into English)
 
 
54, rue La Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes  ☐            No  ☒
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- 




In July 2022, Sanofi issued the financial statements and half year management report attached hereto as Exhibit 99.1 and 99.2 which are incorporated herein by reference.


2022 HALF-YEAR FINANCIAL REPORT

Table of Contents

1.2
CONSOLIDATED BALANCE SHEETS – ASSETS
2
CONSOLIDATED BALANCE SHEETS — SHAREHOLDERS’ EQUITY AND LIABILITIES
3
CONSOLIDATED INCOME STATEMENTS
4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
5
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
6
CONSOLIDATED STATEMENTS OF CASH FLOWS
9
NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022
11
INTRODUCTION
11
A/ Basis of preparation of the half-year financial statements and accounting policies
11
B/ Significant information for the first half of 2022
15
C/ Events subsequent to June 30, 2022
39
2HALF-YEAR MANAGEMENT REPORT40
A/ Significant events of the first half of 2022
40
B/ Progress on implementation of the Corporate Social Responsibility strategy44
C/ Events subsequent to June 30, 2022
48
D/ Consolidated financial statements for the first half of 2022
49
E/ Risk factors and related party transactions66
F/ Outlook67
G/ Appendix – Research and Development Pipeline69
3STATUTORY AUDITORS’ REPORT72
4RESPONSIBILITY STATEMENT OF THE CERTIFYING OFFICER – HALF-YEAR FINANCIAL REPORT73


Exhibit List


Exhibit No.Description
Exhibit 99.1
Condensed half-year consolidated financial statements for 2022
Exhibit 99.2
2022 Half-year management report, Statutory Auditors’ Report and Responsibility Statement






Exhibit Index


Exhibit No.Description
Exhibit 99.1
Condensed half-year consolidated financial statements for 2022
Exhibit 99.2
2022 Half-year management report, Statutory Auditors’ Report and Responsibility Statement





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 28, 2022
SANOFI
By:/s/ Alexandra Roger
Name:Alexandra Roger
Title:Head of Securities Law and Capital Markets



Exhibit 99.2

TABLE OF CONTENTS
2HALF-YEAR MANAGEMENT REPORT
A/ Significant events of the first half of 2022
B/ Progress on implementation of the Corporate Social Responsibility strategy
C/ Events subsequent to June 30, 2022
D/ Consolidated financial statements for the first half of 2022
E/ Risk factors and related party transactions
F/ Outlook
G/ Appendix – Research and Development Pipeline
3STATUTORY AUDITORS’ REPORT
4RESPONSIBILITY STATEMENT OF THE CERTIFYING OFFICER – HALF-YEAR FINANCIAL REPORT




2. HALF-YEAR MANAGEMENT REPORT

A/ SIGNIFICANT EVENTS OF THE FIRST HALF OF 2022
A.1. FIRST-HALF OVERVIEW
During the first half of 2022, Sanofi continued to implement its new “Play to Win” strategy, involving major decisions and positive actions that will support and rebuild the competitive margins necessary for Sanofi to continue to deliver on its mission. Significant events connected with the implementation of that strategy are described below (for additional information on developments related to Research and Development see also section “A.2. Research and Development” below).
On January 7, 2022, Sanofi announced a research collaboration and license agreement with Exscientia to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscentia’s end-to-end AI-driven platform using actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.
On February 3, 2022, Sanofi unveiled a bold new unifying visual identity that epitomizes the modernization and transformation launched by the company in December 2019. With roots in a variety of diverse companies, Sanofi is today a combination of many cultures, identities, and brands. Its new visual identity is rooted in this heritage and brings this diverse history together in a single common brand for the first time. This latest step on the company’s journey symbolizes an ambitious strategy for the future.
On February 8, 2022, Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc (Amunix), adding a promising pipeline of T-cell engager immunotherapies and cytokine therapies. The acquisition also gives Sanofi access to Amunix’s Pro-XTENTM, XPAT, and XPAC technologies to deliver next-generation Conditionally Activated Biologics. This technology platform is highly complementary to Sanofi’s existing R&D platforms, and is a perfect fit for Sanofi’s efforts to accelerate and expand its contribution to developing innovative medicines for oncology patients, with approximately 20 molecules currently in development.
On February 23, 2022, Sanofi and GSK announced their intention to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine: (i) final analysis of data from the global VAT02 booster trial confirmed the vaccine candidate’s universal ability to boost neutralizing antibodies 18-to-30-fold regardless of the platform used for primary vaccination (mRNA or adenovirus); (ii) the VAT08 Phase 3 primary series trial demonstrated that two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated efficacy of 100% against severe COVID-19 disease and hospitalizations, 75% against moderate or severe COVID-19 disease, and 57.9% against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in an environment dominated by numerous variants; and (iii) the trials demonstrated a favorable safety profile following both primary and booster vaccination.
On March 8, 2022, Sanofi was recognized as one of the most sustainability-committed companies in an Environment, Social, Governance (ESG) evaluation performed by Standard & Poor’s Global Ratings (S&P). The ESG Evaluation awarded Sanofi a score of 86 points out of 100, one of the highest scores across all sectors globally. Sanofi’s ESG profile earned 80 points for its solid fundamentals, supplemented by an additional strong preparedness opinion of 6 points awarded for the company’s “excellent awareness of risks and opportunities” and capacity to "anticipate and adapt to a variety of long-term plausible disruptions”.
On March 15, 2022, Sanofi and Blackstone (NYSE: BX) announced a strategic risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will invest up to €300 million to accelerate the global pivotal studies and clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa® to treat patients with multiple myeloma (MM), due to start on schedule in the second half of 2022.
On March 16, 2022, Sanofi and Seagen Inc. (Nasdaq: SGEN) announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein, and Sanofi currently has one ADC in development.
During the March 29, 2022 investor conference, Sanofi gave an update on how the company is advancing its immunology strategy, including its ambition to more than quadruple sales from the Immunology franchise by the end of the decade. The focus of the event was on Dupixent® (dupilumab), a key growth driver for Sanofi, and on the company’s rapidly advancing pipeline which features dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas. Sanofi has raised its peak sales ambition for Dupixent® to more than €13 billion. This new ambition does not include the potential for further upgrades to the sales ambition from chronic obstructive pulmonary disease (COPD), with pivotal readouts from clinical trials in this indication anticipated in 2023.
On March 29, 2022, Sanofi (NASDAQ: SNY) and IGM Biosciences, Inc. (Nasdaq: IGMS) announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies and have ten binding sites, as opposed to conventional IgG antibodies that have only two target binding sites.
40
SANOFI 2021 HALF-YEAR FINANCIAL REPORT


On March 30, 2022, Sanofi finalized the terms of a dual-tranche €1.5 billion bond issue. This includes an inaugural issue of sustainability-linked bonds for a nominal amount of €650 million, linked to Sanofi’s commitment to improve access to essential medicines in low- and lower-middle-income countries via its non-profit global health unit. This issue demonstrates Sanofi’s commitment to society, and to ensure access to healthcare for the world’s most vulnerable people.
On April 4, 2022, Sanofi launched its Diversity, Equity & Inclusion (DE&I) Board, the first of its kind in the pharmaceutical industry to feature outside advisors. Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space, as Board members appointed for a three-year term: organizational psychologist and best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand.
On April 26, 2022, Sanofi announced that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of its ambition to attain world-class standards of manufacturing excellence. Following a successful pilot in 2021 with McLaren Racing, both companies have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production lines across all technologies. Learnings from this partnership will provide insights and develop best practices for manufacturing that will then be implemented across Sanofi’s global industrial network .
On May 4, 2022, Sanofi launched Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to promote health for current and future generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines.
On May 30, 2022, the US Food and Drug Administration (FDA) informed Sanofi that its planned Actual Use Trial (AUT) to support the prescription to over-the-counter switch for Cialis® (tadalafil) had been placed on clinical hold due to matters surrounding the protocol design. Sanofi’s AUT has not yet recruited any patients. Sanofi continues to work with the FDA to move the Cialis® program forward and will engage with the FDA in upcoming meetings to determine the next steps.
On June 2, 2022, Sanofi announced the restructuring of its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron). Under the amended and restated license and collaboration agreement, Regeneron will obtain worldwide exclusive license rights to Libtayo®. The Sanofi and Regeneron global immuno-oncology license and collaboration agreement was originally signed in 2015. Prior to June 2, 2022, the companies had split Libtayo® worldwide operating profits equally and co-commercialized Libtayo® in the US, with Sanofi solely responsible for commercialization in the rest of the world. In return, Sanofi will receive an upfront payment of $900 million and an 11% royalty on worldwide net sales of Libtayo®. Sanofi will also be eligible for a regulatory milestone payment of $100 million, as well as sales-related milestone payments of up to $100 million over the next two years.
On June 8, 2022, Sanofi announced the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company. The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
On May 3, 2022, Sanofi's General Meeting of Shareholders approved the decision to distribute approximately 58% of the share capital of EUROAPI, a European leader in the development, manufacture, marketing and distribution of Active Pharmaceutical Ingredients (APIs), in the form of an exceptional dividend in kind to Sanofi shareholders. On the dividend payment date of May 10, 2022 (further to the admission of EUROAPI shares to listing on the regulated market of Euronext Paris on May 6, 2022), Sanofi divested control over EUROAPI and its subsidiaries, resulting in their deconsolidation from the Sanofi consolidated financial statements as of that date. On June 17, 2022 (the date of delivery of the EUROAPI shares to the French State via the French Tech Souveraineté fund), EPIC BPIFrance acquired a 12% equity interest in EUROAPI. Following completion of those transactions, Sanofi retains an equity interest of 30.1% in EUROAPI, which has been accounted for using the equity method since the date of loss of control.

Net sales for the first half of 2022 amounted to €19,790 million, 14.2% higher than in the first half of 2021. At constant exchange rates (CER)1, net sales rose by 8.4%, driven mainly by strong performances for Dupixent®. The year-on-year increase also reflects good performances by the Consumer Healthcare franchise, including robust growth for the Cough & Cold category; and growth for the Vaccines franchise, driven largely by a recovery in sales of Travel and Polio vaccines compared to 2021.
Net income attributable to equity holders of Sanofi amounted to €3,184 million, versus €2,764 million in the first half of 2021. Earnings per share was €2.55, versus €2.21 for the first half of 2021. Business net income2 was €4,594 million, up 22.6% on the first half of 2021, while business earnings per share (business EPS2) was 22.7% higher than in the first half of 2021 at €3.68.

A.2. RESEARCH AND DEVELOPMENT
Highlights of Sanofi’s Research and Development efforts in the first half of 2022 in the Specialty Care unit included several US and EU regulatory approvals for Dupixent® (dupilumab) for the treatment of eosinophilic esophagitis (EoE), and expanding the severe asthma indication to children aged 6 to 11 years, as well as the moderate-to-severe atopic dermatitis (AD) indication to children aged 6 months to 5 years. In addition, an application for approval of prurigo nodularis has been filed in the US.
In chronic spontaneous urticaria (CSU), the Phase III Study B from the CUPID program evaluating Dupixent® in patients who were refractory to omalizumab was stopped due to futility based on a pre-specified interim analysis. Although positive numerical trends in reducing itch and hives were observed, the results from the interim analysis did not demonstrate statistical significance for the primary endpoints. The previously reported Phase III trial (Study A), which evaluated a different group of patients who were biologic-naïve, met its primary and all key secondary endpoints at 24 weeks, showing that adding Dupixent® to standard-of-care antihistamines significantly reduced itch and hives compared to antihistamines alone. Sanofi remains committed to advancing Dupixent® for patients with CSU on antihistamines and is evaluating next steps.
Efanesoctocog alfa, a once-weekly recombinant factor VIII therapy for the treatment of people with hemophilia A, met both primary and secondary endpoints in previously treated patients ≥12 years of age. The results showed a clinically meaningful prevention of bleeds over a period of 52 weeks, with a median annualized bleeding rate (ABR) of 0 and a mean ABR of 0.71, and a superiority to prior prophylactic
1 Non-GAAP financial measure: see definition in D.3., “Net sales”.
2 Non-GAAP financial measure: see definition in D.2., “Business net income”.
                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
41


factor VIII replacement therapy based on intra-patient comparison. An application for approval was submitted to the FDA. Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA.
In Oncology, the pivotal Phase II AMEERA-3 clinical trial evaluating amcenestrant monotherapy compared to endocrine treatment in patients with locally advanced or metastatic ER+/HER2- breast cancer who progressed on or after hormonal therapies did not meet its primary endpoint of improving progression-free survival (PFS). No new safety signals were observed. In addition, the Phase III clinical trial evaluating the efficacy and safety of amcenestrant compared with tamoxifen in patients with HR+ early breast cancer who have discontinued adjuvant aromatase inhibitor (AI) therapy due to treatment related toxicity (AMEERA-6), enrolled its first participants.
For the treatment of patients with relapsed Multiple Myeloma, latest results from the IKEMA clinical trial evaluating Sarclisa® (isatuximab), in combination with carfilzomib and dexamethasone (Kd), demonstrated a median progression free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone, as evaluated by an Independent Review Committee.
In Neurology, in late June 2022, the FDA placed a partial clinical hold on the Phase III studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis (MG). As a result, new enrolment in the US was paused, and participants in the US who had been in the trial for fewer than 60 days had the study drug suspended. Meanwhile, more than two thousand previously enrolled patients around the globe are continuing to receive tolebrutinib. In early July 2022, the FDA provided written notification to Sanofi requesting information pertaining to additional analyses of clinical safety data and some preclinical data. After submission of the response, the FDA can take up to 30 days to render their decision on whether they agree to lift the partial clinical hold, which could occur as early as the fourth quarter of 2022. In the meantime, enrolment in the clinical program continues with revised study protocols, including enhanced safety monitoring, in most countries. Sanofi is working closely with the independent data monitoring committee members and investigators around the world to evaluate the effectiveness of these safety measures.

For an update on our research and development pipeline, refer to Section G/ of this half-year management report.

A.3. OTHER SIGNIFICANT EVENTS
A.3.1 CORPORATE GOVERNANCE
The Combined General Shareholders’ Meeting of Sanofi was held on May 3, 2022 at Paris Expo Porte de Versailles, under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the individual company and consolidated financial statements for the year ended December 31, 2021, and also resolved to distribute an ordinary annual dividend of €3.33 per share and an additional dividend in kind in the form of an allocation of EUROAPI shares, at a ratio of one (1) EUROAPI share per twenty-three (23) Sanofi shares held. The payment of the dividend, including both the cash dividend and the dividend in kind, was made on May 10, 2022. The General Meeting also reappointed Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp as Directors, and approved the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent directors. The Board of Directors is comprised of 16 members, of whom six are women and two are Directors representing employees. The Board of Directors retains a large majority of independent Directors.

A.3.2. LEGAL AND ARBITRATION PROCEEDINGS
For a description of the most significant developments in legal and arbitration proceedings since publication of the financial statements for the year ended December 31, 2021, refer to Note B.14. to the condensed half-year consolidated financial statements.
The following events have occurred in respect of litigation, arbitration and other legal proceedings in which Sanofi and its affiliates are involved: 
PATENTS
Lantus® Mylan Patent Litigation (United States)
Mylan (now Viatris) and Biocon announced the launch of their interchangeable pen and vial products in November 2021. The proceedings concerning US Patent Nos. 8,603,044, 8,679,069, 8,992,486, 9,526,844, and 9,604,008 are now closed.

GOVERNMENT INVESTIGATIONS AND RELATED LITIGATION
In the New Mexico action concerning the sale and marketing of Plavix®, the state court trial is scheduled to commence in January 2023.
Sanofi US received a new Civil Investigative Demand (CID) requesting the production of documents and information relating to Sanofi’s trade and pricing practices for its insulin products and/or Lantus®-related litigation:
Illinois State Attorney General’s office (CID issued in July 2022, covering the period from 2003 to present).
Insulin Related Litigation
The Harris County, Texas vs. Sanofi-Aventis US LLC, et al. case was dismissed with prejudice in March 2022.
The Miami, Florida vs. Eli Lilly & Co. et al. case was dismissed with prejudice in May 2022.
In May 2022, the Attorney General of Arkansas filed a complaint against the three insulin manufacturers, including Sanofi US, and the three largest Pharmacy Benefit Managers (PBMs) (CVS, ESI, and Optum). The complaint is largely identical to the complaint filed by Mississippi. Arkansas purports to sue both on behalf of itself and in its parens patriae capacity. It asserts claims under the Arkansas Deceptive Trade Practices Act, as well as claims for unjust enrichment and civil conspiracy.
                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
42



A.3.3. OTHER EVENTS
On June 7, 2022. Sanofi launched Action 2022, a global employee share ownership plan open to 86,000 employees in 59 countries. The program, like those carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company.
The shares were offered at a subscription price of €80.21, representing a 20% discount to the average of the 20 opening prices of Sanofi shares from May 9 to June 3, 2022. In addition, for every five shares subscribed, employees were entitled to receive one free share (up to a maximum of four free shares per employee). Each employee was able to purchase up to 1,500 Sanofi shares, subject to the maximum legal limit set at 25% of their gross annual salary minus any voluntary payments already made under employee savings schemes (Group Savings Plan and/or Group Retirement Savings Plan) during 2022.

                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
43



B/ PROGRESS ON IMPLEMENTATION OF THE CORPORATE SOCIAL RESPONSIBILITY STRATEGY

Sanofi continues its progress to improve access to medicines
Sanofi’s Global Health Unit has announced the establishment of a fund and the launch of Impact®
Sanofi Global Health has announced the launch of Impact®, a new brand of standard-of-care medicines produced by Sanofi and dedicated to non-profit distribution to at-risk populations in the world’s most impoverished countries. The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amongst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.
Sanofi has also announced the establishment of an Impact fund that will support start-up companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. By providing inclusive business financing and technical assistance, the fund will complement Sanofi Global Health’s mission of leveraging global, regional and local investment to support the training of healthcare professionals and aiding communities in running sustainable care systems.

Sanofi expands access for underserved communities in the US
Uninsured people living with diabetes in the United States will be able to obtain Sanofi insulins (Lantus®, Insulin Glargine U-100, Toujeo®, Admelog®, and Apidra®) from Sanofi’s Insulins Valyou Savings Program with a valid prescription for a fixed price of $35 for a 30-day supply. This is an enhancement to the program, which previously offered a 30-day supply of Sanofi insulins for $99, comprising ten boxes of SoloStar pens and/or 10 mL vials or 5 boxes of Max SoloStar pens.
The Insulins Valyou Savings Program has helped thousands of people living with diabetes save on their prescription costs since its launch in 2018. In 2021, the program was used over 97,000 times, and provided more than $37 million in savings to people living with diabetes.
This upgrade extends the scope of the program.

Sanofi joins the Beacon of Hope program to address racial inequities in clinical trials, health, and education
Sanofi has announced a collaboration with the Beacon of Hope program to address the root causes of disparities in health and education and to create greater diversity, equity and inclusion across R&D in the pharmaceutical industry.
Racial and ethnic minorities have historically been marginalized in clinical research. Sanofi recognizes and supports the urgency to change this situation and help correct this disparity in clinical trial participation.
Launched in July 2021 as a $33.7 million commitment from Novartis and the Novartis US Foundation, Beacon of Hope began as a 10-year collaboration with Morehouse School of Medicine and 26 other Historically Black Colleges and Universities, the Thurgood Marshall College Fund, Coursera, and the National Medical Association, to work together to increase diversity among clinical trial participants and investigators; improve access to high-quality education and promising jobs; address inherent bias in the data standards used to diagnose and treat disease; and find actionable solutions to environmental and climate issues that disproportionately affect health among communities of color.

Access and Pricing Principles at Sanofi
Sanofi has a long history of working with healthcare systems to make its treatments accessible and affordable to patients in need. We understand and share concerns about the affordability of medicines for patients, and encourage countries to improve value in healthcare spending. However, we firmly believe that the pharmaceutical industry is only one of many stakeholders in the healthcare system that can and should contribute to this goal. Given the growing concerns over rising healthcare costs, we have developed an approach to pricing that reflects our commitment to broadly expanding patient access to medicines and vaccines while maintaining sustainable investment in Research & Development. Our Access & Pricing Principles are founded on two pillars:
Clear rationale for pricing and access at the launch of a new medicine or vaccine
Building affordability criteria into pricing considerations for new launches

When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes consultation with external stakeholders and considers the following factors:
Holistic assessment of the product’s value (clinical, social, wellbeing and economic value)
Availability of similar treatments at the time of launch
Ability of market to afford the product
Other factors specific to the product at the time of launch
                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
44



We disclose more information on our global access and pricing principles on our global website, and on our US pricing policy on the Sanofi US website.

Sustainability-linked bond tied to Sanofi’s Access commitments
Sanofi is committed to integrate sustainability within its Play to Win business strategy, as well as within its investment and financing strategy. More than a year after issuing its first sustainability-linked credit revolving facilities, Sanofi successfully placed an inaugural issue of sustainability-indexed bonds linked to access to medicines. The issue, with a nominal amount of €650 million, is tied to Sanofi’s commitment to improve access to essential medicines in low- and lower-middle-income countries via its Global Health non-profit unit. This issue demonstrates Sanofi’s commitment to society, and to ensure access to healthcare for the world’s most vulnerable people.

Building partnerships to support Sanofi’s pediatric cancer commitment
In its flagship childhood cancer program, Sanofi aims to work collaboratively across sectors, to advance knowledge in pediatric studies.
In the research field, Sanofi is now one of the partners of the Pediatric Pre-clinical Proof of Concept Platform (ITCC-P4), which aims to enable state-of-the-art upfront preclinical testing of novel molecularly targeted compounds. Sanofi has recently engaged in a Pediatric Oncology Relevant Target collaboration led by the Foundation for the National Institutes of Health (FNIH) to review and prioritize targets.
For the development of innovative clinical trials, Sanofi works closely with experts at MD Anderson Cancer Center, Institut Gustave Roussy, Children's Hospital of Philadelphia, Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. All of these efforts are centered on patient needs, as highlighted by Sanofi’s support for childhood cancer advocacy groups including Coalition Against Childhood Cancer (CAC2) and Imagine for Margo.

Sanofi continues its progress to limit its impact on the environment
New CO2 Scope 3 emissions reduction target
As Sanofi’s ambitious strategy to minimize its environmental impacts – including on climate change – delivers important progress, we have upgraded our Scope 3 greenhouse gas (GHG) emissions reduction target from the initial 14% to 30% by 2030, as part of our ambition to achieve carbon neutrality by 2030.
In the third quarter of 2021, we pledged to achieve carbon neutrality by 2030 across all our operations and our entire value chain, as well as net zero greenhouse gas emissions by 2050. This brought our target date forward by 20 years compared with our previous pledge, made in 2015 after COP21 and the Paris Agreement. As part of this ambition, GHG reduction targets versus the 2019 baseline were set at 55% by 2030 for operations (Scopes 1 & 2) and at 14% for the value chain (Scope 3). Those goals have been validated by the Science Based Target initiative (SBTi). Sanofi submitted the Net-Zero Target and the upgraded Scope 3 reduction target to SBTi for validation last May.

Evolutive Vaccine Facility in Singapore: low energy intensity and 100% electrified by design
Building a path towards carbon neutrality is not only about revamping or optimizing existing facilities, but also about designing new factories with the lowest possible environmental footprint.
Our new vaccine facility in Singapore maximized its energy efficiency by including energy recovery in all processes. It is 100% electrified, with gas boilers replaced by heat pumps and energy recovery in all processes. All available surfaces are equipped with solar panels to generate renewable electricity. The remaining electricity supply will be sourced from renewable alternatives such as long-term power purchase agreements and renewable energy certificates, with the objective to source 100% renewable electricity by 2030, in line with our RE100 commitment.

ESG dashboard as of the second quarter of 2022
In 2020, when Sanofi renewed its CSR ambitions, we reviewed and updated our portfolio of initiatives. The numbers shown below highlight ongoing progress in the implementation of our integrated CSR strategy.
Data on YTD basis unless stated otherwise

Affordable access
Sanofi Global Health, a non-profit unit formed within the company in April 2021, aims to provide 30 of Sanofi's medicines across a wide range of therapeutic areas to patients in 40 of the lowest income countries. Beyond the products provided, Sanofi Global Health works on integrating programs that ensure optimal care management over time for patients.
Sanofi is also committed to helping 1,000 patients living with rare diseases who have no access to treatments, and will donate 100,000 vials of medicine for their treatments each year. This continues Sanofi’s 30-year commitment to patients suffering from rare diseases, such as Fabry, Gaucher or Pompe diseases, for which access to treatment is often limited.
The third initiative on access is to develop a global access plan for all new products, making them available in selected relevant markets within two years of launch.

                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
45


Affordable access
Sanofi Global Health
Q1 2022
Q2 2022
Malaria
1,024,170 patients treated
8 countries

1,693,770 patients treated
10 countries
Tuberculosis
35,094 patients treated
11 countries

76,634 patients treated
13 countries
Non-communicable diseases
46,300 patients treated
12 countries
85,956 patients treated
21 countries
Rare disease vial donations
Q1 2022
Q2 2022
# Patients treated9981,015
#Vials donated22,68251,370
Global Access Plan
Q1 2022
Q2 2022
# of access plan
Pilot phase and blueprint completed

R&D for unmet needs
Sanofi continues its efforts to fight polio and sleeping sickness, two of its legacy programs that address global health issues.
We have been involved in the fight against polio from the beginning, and continue to play a critical role in the delivery of polio vaccines. We have also committed to collaborate with the WHO to eliminate sleeping sickness by 2030.
Part of Sanofi’s R&D ambition is to develop innovative medicines to eliminate cancer deaths in children.
R&D for unmet needs
Eradicate Polio
Q1 2022
Q2 2022
# Inactivated Polio Vaccine (IPV) doses supplied
16 million IPV doses supplied to UNICEF for GAVI countries
27 million IPV doses supplied to UNICEF for GAVI countries

Sleeping sickness elimination
FY 2020
FY 2021
# Patients tested
1.6 million
2 million
# Patients treated663805
Pediatric cancer treatment development
Q1 2022
Q2 2022
# of assets identified
1 of the 2 assets in protocol preparation for clinical study
1 asset in pre-clinical assessments
1 asset in protocol preparation for clinical study

                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
46


Planet care
To contribute to better resource conservation, Sanofi plans to remove all plastic blister packs for its syringe vaccines by 2027. In addition, we are committed to eco-designing all our new products by 2025. To reduce our greenhouse gas emissions by 55% by 2030, all Sanofi sites will use 100% electricity from renewable sources and we have also set a target of carbon neutrality for our car fleet, both by 2030.
Planet Care
Blister free vaccines
Q1 2022
Q2 2022
% blister free syringe vaccines
29% of vaccines produced are blister free

Data updated annually
Eco design
Q1 2022
Q2 2022
# of Life Cycle Analysis (LCA)
4 LCAs completed & 1 in progress
Eco-design digital solutions project launched

5 LCAs completed & 3 in progress
Eco-design digital solutions project in progress
Scope 1 & 2 emissions
Q1 2022
Q2 2022
GHG reduction vs 2019 %-26%-27%
Renewable electricity
Q1 2022
Q2 2022
% electricity consumption from renewable sources
60%1
60%
Eco car fleet
Q1 2022
Q2 2022
% eco car fleet vs. total car fleet
28.7% eco-fleet
30.4% eco-fleet
1 Baseline recalculated following the spin-off of EUROAPI

In and beyond the workplace
As a global company, we are committed to ensuring that our leaders reflect the communities and patients we serve. We are committed to continue fostering an organization where all employees have equal opportunities to reach positions of responsibility within the company. Our ambition is to have 40% of women in top executive roles and 50% of women in senior leadership roles by 2025. We are continuing our social and economic engagement in the communities where we operate in. Finally, we are embedding our commitment to society in our leaders’ career development paths to strengthen the social impact of their decisions.
In and beyond the workplace
Q1 2022
Q2 2022
Diverse Senior Leadership
% of women
35.1% of our executives
40.4% of our senior leaders were women
35.9% of our executives
41.1% of our senior leaders
were women
Engagement with communities
Q1 2022
Q2 2022
# volunteers
4,975 volunteers
1,998 volunteers
# hours
26,906 hours
12,687 hours
From Leaders to Citizens
Q1 2022
Q2 2022
KPIRoll out planned in 2022

                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
47


ESG ratings
The ongoing implementation of our social impact strategy has led in recent months to a range of positive updates of the our rank or grade in most of the ESG rankings.
image.jpg

C/ EVENTS SUBSEQUENT TO JUNE 30, 2022

Following clearance from the antitrust authorities, the exclusive licensing rights to Libtayo® have been definitively transferred to Regeneron with effect from July 1, 2022.
Sanofi Global Health announced on July 4, 2022 the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries.
Sanofi announced on July 10, 2022 that the Phase III ATLAS-PPX study evaluating the efficacy and safety of once-monthly fitusiran (80 mg) in adults and adolescents with severe hemophilia A or B who were previously treated with prior factor or bypassing agent (BPA) prophylaxis had met the primary endpoint and demonstrated that fitusiran prophylaxis significantly reduced bleeding episodes compared to prior factor or BPA prophylaxis.
On July 10, 2022, Sanofi and Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) presented for the first time, in a late-breaking session at the 30th International Society on Thrombosis and Haemostasis (ISTH) Congress, positive results from the XTEND-1 pivotal Phase III study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001), an investigational factor VIII replacement therapy, in previously treated adults and adolescents aged 12 years and over with severe hemophilia A.
On July 14, 2022, Sanofi announced that the Phase III trial assessing the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) had met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens. There are no approved treatments for children with EoE under 12 years of age.
                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
48


D/ CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST HALF OF 2022
Unless otherwise indicated, all financial data in this report are presented in accordance with international financial reporting standards (IFRS), including international accounting standards and interpretations (see Note A.1. to the condensed half-year consolidated financial statements).

Consolidated income statements for the six months ended June 30, 2021 and June 30, 2022
(€ million)June 30, 2022 (6 months)as % of net salesJune 30, 2021 (6 months)
(a)
as % of net sales
Net sales19,790 100.0 %17,335 100.0 %
Other revenues1,005 5.1 %596 3.4 %
Cost of sales(6,130)(31.0)%(5,542)(32.0)%
Gross profit14,665 74.1 %12,389 71.5 %
Research and development expenses(3,147)(15.9)%(2,663)(15.4)%
Selling and general expenses(4,953)(25.0)%(4,531)(26.1)%
Other operating income416 

410 
Other operating expenses(1,204)

(709)
Amortization of intangible assets(910)

(775)
Impairment of intangible assets(87)

(178)
Fair value remeasurement of contingent consideration(17)

(4)
Restructuring costs and similar items(792)

(343)
Other gains and losses, and litigation(142)

— 
Operating income3,829 19.3 %3,596 20.7 %
Financial expenses(189)

(188)
Financial income34 

28 
Income before tax and investments accounted for using the equity method3,674 18.6 %3,436 19.8 %
Income tax expense(495)

(678)
Share of profit/(loss) from investments accounted for using the equity method58 

26 
Net income3,237 16.4 %2,784 16.1 %
Net income attributable to non-controlling interests53 

20 

Net income attributable to equity holders of Sanofi3,184 16.1 %2,764 15.9 %
Average number of shares outstanding (million)1,250.0 

1,250.3 

Average number of shares after dilution (million)1,255.3 

1,255.6 

Basic earnings per share (in euros)
2.55 

2.21 

Diluted earnings per share (in euros)
2.54 

2.20 

(a)Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1 to the consolidated financial statements for the year ended December 31, 2021. Those impacts were not material as of June 30, 2021.
                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
49


D.1. SEGMENT INFORMATION
D.1.1. OPERATING SEGMENTS
In accordance with IFRS 8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators. The operating segment disclosures required under IFRS 8 are provided in Note B.20. to the condensed half-year consolidated financial statements.
Sanofi has three operating segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
The Pharmaceuticals segment comprises, for all geographical territories, the commercial operations of the following global franchises: Specialty Care (Dupixent®, Neurology & Immunology, Rare Diseases, Oncology, and Rare Blood Disorders) and General Medicines (Core Assets and Non-Core Assets), together with research, development and production activities dedicated to the Pharmaceuticals segment. This segment also includes associates whose activities are related to pharmaceuticals.
The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.
The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products.
Inter-segment transactions are not material.
The costs of Sanofi’s global support functions (External Affairs, Finance, Human Resources, Legal Affairs, Information Solutions & Technologies, Sanofi Business Services, etc.) are mainly managed centrally at group-wide level. The costs of those functions are presented within the “Other” category. That category also includes other reconciling items such as retained commitments in respect of divested activities.

D.1.2. BUSINESS OPERATING INCOME
We report segment results on the basis of “Business operating income”. This indicator is used internally by Sanofi’s chief operating decision maker to measure the performance of each operating segment and to allocate resources. For a definition of “Business operating income”, and a reconciliation between that indicator and Income before tax and investments accounted for using the equity method, refer to Note B.20.1.2. to our condensed half-year consolidated financial statements.
In the first half of 2022, “Business operating income” amounted to €5,818 million (versus €4,902 million for the first half of 2021), while “Business operating income margin” was 29.4% (versus 28.3% for the first half of 2021). “Business operating income margin” is a non-GAAP financial measure that we define as the ratio of “Business net income” to our consolidated net sales.
Because our “Business operating income” and “Business operating income margin” are not standardized measures, they may not be directly comparable with the non-GAAP financial measures of other companies using the same or similar non-GAAP financial measures. Despite the use of non-GAAP measures by management in setting goals and measuring performance, these are non-GAAP measures that have no standardized meaning prescribed by IFRS.


                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
50


D.2. BUSINESS NET INCOME
We believe that understanding of our operational performance by our management and our investors is enhanced by reporting “Business net income”. This non-GAAP financial measure represents “Business operating income”, less net financial expenses and the relevant income tax effects.
“Business net income” for the first half of 2022 amounted to €4,594 million, 22.6% more than in the first half of 2021 (€3,747 million). That represents 23.2% of net sales, versus 21.6% for the first half of 2021.
We also report “Business earnings per share” (business EPS), a non-GAAP financial measure which we define as business net income divided by the weighted average number of shares outstanding.
Business EPS was €3.68 for the first half of 2022, 22.7% higher than the 2021 first-half figure of €3.00, based on an average number of shares outstanding of 1,250.0 million for the first half of 2022 and 1,250.3 million for the first half of 2021.
The table below reconciles our “Business operating income” to our “Business net income”:
(€ million)June 30, 2022 (6 months)June 30, 2021 (6 months)
(a)
December 31, 2021 (12 months)

Business operating income5,818 4,902 10,714 
Financial income and expenses(155)(160)(328)
Income tax expense(1,069)(995)(2,173)
Business net income4,594 3,747 8,213 
(a) Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1 to the consolidated financial statements for the year ended December 31, 2021. Those impacts were not material as of June 30, 2021.


We define “Business net income” as Net income attributable to equity holders of Sanofi determined under IFRS, excluding the following items:
amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature);
fair value remeasurements of contingent consideration relating to business combinations (IFRS 3) or divestments;
expenses arising from remeasurement of inventories following a business combination (IFRS 3);
restructuring costs and similar items (presented within the income statement line item Restructuring costs and similar items);
other gains and losses, including gains and losses on major disposals of non-current assets (presented within the income statement line item Other gains and losses, and litigation);
other costs or provisions relating to litigation (presented within the income statement line item Other gains and losses, and litigation);
the tax effects of the items listed above, and the impact of major tax disputes;
shares of profits and losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has entered into a strategic partnership agreement;
the effects of acquisitions and restructuring costs on investments accounted for using the equity method (for joint ventures and associates with which Sanofi has entered into a partnership agreement);
the portion of the items listed above attributable to non-controlling interests.

                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
51


The table below reconciles our “Business net income” to Net income attributable to equity holders of Sanofi:
(€ million)June 30, 2022 (6 months)June 30, 2021 (6 months)
(c)
December 31, 2021 (12 months)

Net income attributable to equity holders of Sanofi3,184 2,764 6,223 
Amortization of intangible assets (a)
910 775 1,580 
Impairment of intangible assets
87 178 192 
Fair value remeasurement of contingent consideration17 
Expenses arising from the impact of acquisitions on inventories— 
Restructuring costs and similar items792 343 820 
Other gains and losses, and litigation (b)
142 — 
Tax effects of the items listed above:(573)(316)(614)
amortization and impairment of intangible assets
(218)(230)(415)
fair value remeasurement of contingent consideration
(18)(2)
tax effects of restructuring costs and similar items
(199)(89)(200)
other tax effects
(138)— 
Other items32 (1)(1)
Business net income4,594 3,747 8,213 
Average number of shares outstanding (million)1,250.0 1,250.3 1,252.5 
Basic earnings per share (in euros)2.55 2.21 4.97 
Reconciling items per share (in euros)1.13 0.79 1.59 
Business earnings per share (in euros)3.68 3.00 6.56 
(a)Includes amortization expense related to accounting for business combinations: €853 million in the six months ended June 30, 2022; €736 million in the six months ended June 30, 2021; and €1,484 million in the year ended December 31, 2021.
(b)In the first half of 2022, this line includes the pre-tax gain on the deconsolidation of EUROAPI (see note B.1. to the condensed half-year consolidated financial statements) and a charge to a provision for risks relating to a litigation.
(c)Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1 to the consolidated financial statements for the year ended December 31, 2021. Those impacts were not material as of June 30, 2021.

The most significant reconciling items between “Business net income” and Net income attributable to equity holders of Sanofi relate to (i) the purchase accounting effects of our acquisitions and business combinations, particularly the amortization and impairment of intangible assets (other than software and other rights of an industrial or operational nature) and (ii) the impacts of restructurings or transactions regarded as non-recurring, where the amounts involved are particularly significant. We believe that excluding those impacts enhances an investor’s understanding of our underlying economic performance, because it gives a better representation of our recurring operating performance.
We believe that eliminating charges related to the purchase accounting effect of our acquisitions and business combinations (particularly amortization and impairment of some intangible assets) enhances comparability of our ongoing operating performance relative to our peers. Those intangible assets (principally rights relating to research, development and commercialization of products) are accounted for in accordance with IFRS 3 (Business Combinations) and hence may be subject to remeasurement. Such remeasurements are not made other than in a business combination.
We also believe that eliminating the other effects of business combinations (such as the incremental cost of sales arising from the workdown of acquired inventories remeasured at fair value in business combinations) gives a better understanding of our recurring operating performance.
Eliminating restructuring costs and similar items enhances comparability with our peers because those costs are incurred in connection with reorganization and transformation processes intended to optimize our operations.
Finally, we believe that eliminating the effects of transactions that we regard as non-recurring and that involve particularly significant amounts (such as major gains and losses on disposals, and costs and provisions associated with major litigation and other major non-recurring items) improves comparability from one period to the next.
We remind investors, however, that “Business net income” should not be considered in isolation from, or as a substitute for, Net income attributable to equity holders of Sanofi reported in accordance with IFRS. In addition, we strongly encourage investors and potential investors not to rely on any single financial measure but to review our financial statements, including the notes thereto, carefully and in their entirety.
We compensate for the material limitations described above by using “Business net income” only to supplement our IFRS financial reporting and by ensuring that our disclosures provide sufficient information for a full understanding of all adjustments included in “Business net income”.
Because our “Business net income” and “Business EPS” are not standardized measures, they may not be directly comparable with the non-GAAP financial measures of other companies using the same or similar non-GAAP financial measures.

                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
52


D.3. NET SALES
Net sales for the first half of 2022 amounted to €19,790 million, 14.2% higher than in the first half of 2021. Exchange rate fluctuations had a positive effect of 5.8 percentage points overall, due mainly to positive trends in the euro exchange rate against the US dollar, Chinese yuan and Brazilian real. At constant exchange rates (CER, see definition below), net sales rose by 8.4%, driven mainly by strong performances for Dupixent®. The year-on-year increase also reflects good performances by the Consumer Healthcare franchise, including robust growth for the Cough & Cold category; and growth for the Vaccines franchise, driven largely by a recovery in sales of Travel and Polio vaccines compared to 2021.
Reconciliation of net sales to net sales at constant exchange rates
(€ million)June 30, 2022 (6 months)June 30, 2021 (6 months)Change
Net sales19,790 17,335 +14.2 %
Effect of exchange rates(1,002)
Net sales at constant exchange rates18,788 17,335 +8.4 %

When we refer to changes in our net sales at constant exchange rates (CER), that means we have excluded the effect of exchange rates by recalculating net sales for the relevant period using the exchange rates that were used for the previous period.
When we refer to changes in our net sales on a constant structure (CS) basis, that means that we eliminate the effect of changes in structure by restating the net sales for the previous period as follows:
by including sales generated by entities or product rights acquired in the current period for a portion of the previous period equal to the portion of the current period during which we owned them, based on historical sales information we receive from the party from whom we make the acquisition;
similarly, by excluding sales for a portion of the previous period when we have sold an entity or rights to a product in the current period; and
for a change in consolidation method, by recalculating the previous period on the basis of the method used for the current period.
To facilitate analysis and comparisons with prior periods, some figures are given at constant exchange rates and on a constant structure basis (CER/CS).

D.3.1. NET SALES BY SEGMENT AND GLOBAL BUSINESS UNIT (GBU)
Our net sales comprise the net sales generated by our Pharmaceuticals, Vaccines and Consumer Healthcare segments. The table below also presents net sales by Global Business Unit (GBU).
(€ million)June 30, 2022 (6 months)June 30, 2021 (6 months)Change on
a reported
basis
Change at
constant
exchange rates
Specialty Care GBU
7,642 5,978 +27.8 %+19.8 %
General Medicines GBU
7,357 7,218 +1.9 %-2.3 %
Pharmaceuticals segment14,999 13,196 +13.7 %+7.7 %
Vaccines GBU/segment2,198 1,937 +13.5 %+7.8 %
Consumer Healthcare GBU/segment2,593 2,202 +17.8 %+13.1 %
Total net sales19,790 17,335 +14.2 %+8.4 %

D.3.2. NET SALES BY GEOGRAPHICAL REGION AND PRODUCT

Net sales by main product and geographical region break down as follows:


                                                                                                                             SANOFI 2022 HALF-YEAR FINANCIAL REPORT
53


(€ million)Net salesChange
(CER)
Change
(reported)
United
States
Change
(CER)
EuropeChange
(CER)
Rest of
the World
Change
(CER)
Dupixent®
3,577 +44.4 %+56.2 %2,653 +38.0 %450 +55.0 %474 +75.5 %
Aubagio®
1,017 -4.4 %+2.3 %689 -6.3 %269 +1.5 %59 -9.4 %
Lemtrada®
45 — %+4.7 %19 -15.0 %12 +9.1 %14 +16.7 %
Kevzara®
172 +46.0 %+52.2 %90 +64.0 %53 +29.3 %29 +36.4 %
Total Neurology & Immunology1,234 +0.7 %+7.3 %798 -1.8 %334 +5.4 %102 +4.1 %
Myozyme®/ Lumizyme®
487 -3.3 %+0.8 %163 -17.8 %206 +2.5 %118 +10.7 %
Nexviazyme®
73 +6700.0 %+7200.0 %63 — %+200.0 %— %
Fabrazyme®
458 +5.8 %+11.2 %221 +5.3 %116 +4.5 %121 +8.1 %
Cerezyme®
367 +5.5 %+7.0 %94 +2.4 %126 +1.6 %147 +11.0 %
Aldurazyme®
133 +4.9 %+8.1 %29 — %45 +4.7 %59 +7.4 %
Cerdelga®
139 +7.3 %+13.0 %75 +6.3 %55 +7.8 %+12.5 %
Total Rare Diseases1,695 +6.7 %+10.9 %645 +7.4 %553 +4.2 %497 +9.0 %
Jevtana®
203 -20.8 %-15.4 %142 +8.4 %19 -74.7 %42 -8.7 %
Sarclisa®
129 +67.6 %+74.3 %55 +78.6 %38 +40.7 %36 +89.5 %
Fasturtec®
86 +8.1 %+16.2 %54 +14.0 %24 +9.1 %-22.2 %
Libtayo®
88 +44.1 %+49.2 %— — %70 +43.8 %18 +45.5 %
Total Oncology507 +7.4 %+13.4 %251 +20.0 %151 -12.8 %105 +20.0 %
Eloctate®
291 -3.2 %+4.7 %232 -2.8 %— — %59 -4.8 %
Alprolix®
237 +9.0 %+18.5 %198 +10.5 %— — %39 +2.6 %
Cablivi®
97 +9.5 %+15.5 %48 +2.3 %47 +17.5 %— %
Total Rare Blood Disorders629 +3.7 %+11.9 %482 +3.8 %47 +17.5 %